Shares of the home infusion provider jumped 22% before market open after the company reached an agreement for a takeover valuing the business at more than $5 billion including debt. Clayton, Dubilier & Rice will own 51% of the combined entity, while McKesson will hold the remaining 49% stake.
McKesson retains the right to purchase the equity stake held by CD&R at a later date. The provider serves more than 315,000 patients across 184 care centers, specializing in specialty drugs for serious infections, cancer, and autoimmune diseases, and shareholders will receive $32.05 per share in the transaction.
